In patients with systemic and/or cutaneous mastocytosis, is omalizumab (Xolair) in addition to standard care more effective in the management of symptoms than standard care alone? A randomized, placebo-controlled, double blind, parallel design study

Trial Profile

In patients with systemic and/or cutaneous mastocytosis, is omalizumab (Xolair) in addition to standard care more effective in the management of symptoms than standard care alone? A randomized, placebo-controlled, double blind, parallel design study

Completed
Phase of Trial: Phase II/III

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Systemic mastocytosis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 11 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 31 Mar 2017 Planned End Date changed from 31 Aug 2016 to 22 Jun 2017.
    • 31 Mar 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top